Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 19, 2011

View Archived Issues

TIGEM describes HDAd-based gene therapy for primary hyperoxaluria type 1 / News in Context

Novel neurotransmitter modulators patented

Top-line phase I data on VRS-859 for type 2 diabetes

VBI Vaccines completes acquisition of Epixis

Zofran may be associated with abnormal heart rhythms

Dovitinib assessed in HER2- breast cancer stratified by FGFR1 and HR amplification statuses

Novel treatment strategy for leukemia targets oncogene upregulation

Phase II trial evaluates FV-100 for pain associated with shingles

Novel protein kinase inhibitors patented by DCAM Pharma

Ono Pharmaceutical secures new Japanese approval for Glactiv

Catabasis Pharmaceuticals identifies new NF-kappa-B activation inhibitors

Vivus reaches agreement with FDA on Qnexa NDA

PROLOR Biotech presents promising preclinical data on FVIIa-CTP

BioLineRx receives European confirmation of regulatory pathway for BL-5010

New antivirals described by Gilead Sciences

New curcumin derivatives reported for Alzheimers disease

Alkermes completes merger with Elan Drug Technologies

Phosphagenics set to begin pivotal trials of TPM technology-delivered oxycodone patch

Karo Bio obtains clearance for phase III trial in HeFH

Spinifex Pharmaceuticals commences phase II study of EMA-401

Merck KGaA acquires exclusive worldwide rights to experimental MS treatment

Bioheart to seek FDA clearance for phase I ANGEL study

SMART-5 trial data reported for bazedoxifene/conjugated estrogens

Pronova BioPharma initiates first-in-human study of PRC-4016

Velcade approved in Japan for new indication

Health Canada issues new approval for Lucentis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 6, 2025.
MJFF grant supports Bexorg’s translational biomarker work
BioWorld Science
Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...
REST emerges as biomarker in ALS, knockdown improves ALS symptoms
BioWorld Science
About 10% of amyotrophic lateral sclerosis (ALS) cases result from inherited genetic mutations, with about 20% of them attributed to mutations in the gene...
Serotonin receptor modulators for the treatment of OUD
BioWorld Science
Opioid use disorder (OUD) causes high morbidity and mortality rates, with fentanyl driving unprecedented overdose rates. Researchers from the University of...
KLF15 shows potential as marker, target for cholangiocarcinoma
BioWorld Science
Researchers at the Biodonostia Health Research Institute reported on the role of KLF15 in cholangiocarcinogenesis and its potential as a therapeutic target in...